Topic drug development

Companies drug development

iCD. Vertriebs GmbH , Germany

iCD. is a pioneer in LIMS and specialized in the development of software and associated consulting services for laboratories of different industry sectors such as pharma & biotechnology since 1986. More than 300 companies worldwide rely on our software solutions in R&D, production, QA/QC, sanitation more

Products drug development

High Performance Crossflow Cassettes Sartocon® ECO with Hydrosart® membrane

Sartocon® ECO is based on Hydrosart® ultrafilter technology that uses cross linked polymer membranes based on hydrophilic cellulose more

Protagen AG: Your reliable partner for biotherapeutical development

UNIchip® allows faster and more efficient selection of monoclonal antibodies and high affinity biotherapeutic reagents with improved specifity and stability in the development phase. more

News drug development

• OctoPlus enters into drug development and manufacturing contract with Ferring Pharmaceuticals A/S

  OctoPlus N.V.  announced that a formulation development and manufacturing contract has been signed with Ferring Pharmaceuticals A/S. The undisclosed contract value will make a material contribution to OctoPlus' 2012 revenues. Further details on the compound and activities are not disclosed. more

• Almirall and BioFocus enter research alliance

  Almirall, S.A. announced that it has formed a research alliance with BioFocus, an affiliate from Galapagos NV.The three-year alliance is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall.  Under the terms of the collaboration, BioFocus will more

• Ironwood Pharmaceuticals and Bionomics announce collaboration research

  Ironwood Pharmaceuticals, Inc. and Bionomics Limited announced that they entered into a collaboration, research, and licensing agreement that will enable Ironwood to develop and commercialize Bionomics’ investigational anti‐anxiety compound BNC210 and other related compounds. The goal of the collabo more

White papers drug development

• Non-Invasive Real-Time Cell Analytics for Drug Discovery
  

  Roche’s xCELLigence Cardio Instrument is a medium-throughput cell analyzer using impedance recording to monitor cardiac beating and cellular events in real time. The instrument features high resolution detection rate and frequency measurement technology driven by dedicated software. Unlike patch clamp recordings, this system monitors cardiac cell responsivity continuously in both short-term and more

• Continuous Real-Time Cell Monitoring in 16- and 96-Well Plates
  

  The xCELLigence System is a microelectronic biosensor system for cell-based assays, providing dynamic, real-time, label-free cellular data for a variety of research applications in drug development, toxicology, cancer research, medical microbiology, and virology. Exceeding the limits of endpoint analysis, data how cells are responding are obtained during the entire experiment more

• Real-time and Dynamic Monitoring of Virus-mediated Cytopathogenicity
  

  To understand overall infectivity, virus progression and disease onset it is important to perform a detailed examination of cytopathic effects. Depending on the type of viruses and cells, different cytopathic effects might be observed dependent on the timepoint of infection (e.g., during the growth or stationary phase) and the amount of virus used. One of the most common methods for measuring lysogenic/lytic activity of viruses is the plaque test [1]. In this assay culture plates with confluent cells that are sensitive towards the specific virus type/strain are used. Lytic activity of a virus is detected by macroscopic analysis of plaques in a confluent cell layer after staining (e.g., with crystal violet). This technique is an end-point assay and it is well-suited to determine viral titers; however, it provides no information about the onset of cytopathic effects and kinetics of the viral replication. Moreover, infection with a number of viruses (e.g., attenuated mutants) leads to the formation of small and more

Publications drug development

• Atrial natriuretic peptides in Han Wistar, Sprague–Dawley and spontaneously Hypertensive rats

  ABSTRACT The atrial natriuretic peptide (ANP) and its precursor (N‐terminal fragment of atrial natriuretic peptide, NT‐proANP) are natriuretic peptides released into the circulation as a consequence of an acute atrial stretch. As for the brain natriuretic peptide and its N‐terminal fragment, the more

• Revealing Interaction Mode between HIV‐1 Protease and Mannitol Analog Inhibitor

  HIV protease is a key enzyme to play a key role in the HIV‐1 replication cycle and control the maturation from HIV viruses to an infectious virion. HIV‐1 protease has become an important target for anti‐HIV‐1 drug development. Here, we used molecular dynamics simulation to study the binding mode b more

• The use of tumour volumetrics to assess response to therapy in anti‐cancer clinical trials

  Abstract Serial evaluations of tumour burden using imaging, mainly computed tomography and magnetic resonance imaging, form the basis for assessing treatment response in many clinical trials of anti‐cancer therapeutics. Traditionally, these evaluations have been based on linear measurements of tu more

Market studies drug development

• Chemizon, Inc. - Strategic SWOT Analysis Review

  Chemizon, Inc. (Chemizon) is a biotechnology company, engaged in the discovery and development of innovative therapeutics. The company owns an integrated drug discovery platform based on medical chemistry, biology, computational chemistry, ADME/DMPK and pharmacology to accelerate drug development pr more

• NeuroDiscovery Limited (NDL) - Financial and Strategic SWOT Analysis Review

  NeuroDiscovery Ltd (NeuroDiscovery) is an Australian-based neuroscience drug development company. It engages in the provision of neuroscience services and in drug development. Its pipeline products include NSL-101 and NSL-043. NSL-101 is a natural product formulation, which the company intends to ou more

• Global Biosimilar Market 2010-2014

  TechNavio’s analysts forecast the Global Biosimilar market to grow at a CAGR of 52.2 percent over the period 2010–2014. One of the key factors contributing to this market growth is the rise in patent expirations of branded biopharmaceuticals. The Global Biosimilar market has also been witnessing the more

Websites drug development